EMA (EU)
GUIDANCE FINAL
ICH M13B guideline on bioequivalence for immediaterelease solid oral dosage forms - additional strengths biowaiver - Step 5
Published: 9/21/2026Detected: 9/21/2026
Summary preview
Provides an ICH/EMA framework to justify bioequivalence (BE) waivers for additional strengths of immediate-release solid oral products when BE/efficacy-safety has been shown for at least one strength.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountclinical
manufacturing
quality
safety
labeling
#ICH M13B
#bioequivalence
#biowaiver
#immediate-release
#solid oral dosage forms
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026